InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) today announced that the two companies, ...

ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has ...

InnoCare & KeyMed jointly enter license agreement with Prolium to develop and commercialize ICP-B02, a CD20xCD3 bispecific antibody: Beijing Tuesday, January 21, 2025, 17:00 Hrs [ ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development ...

U.S.-based Prolium Biosciences has now agreed to pay InnoCare and Keymed $17.5 million in upfront and near-term payments to ...

have jointly entered into an exclusive license agreement with Prolium Bioscience (Prolium) for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

China’s InnoCare Pharma and KeyMed Biosciences and their joint venture have entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January 2025. A total of 92,197,387 warrants were exercised for ...

312, PSL, 10.43 se Monahans; TD 7999; API #42-103-37561 • Carthel 31-TTT-B02-WF #223: Phantom (Wolfcamp)-Horizontal; 1667 fwl, 267 fsel, Sec 82, Blk 33, Abst. 934, H&TC RR, 1.6 sw Mentone ...

In another Chinese newco out-licensing deal, Innocare Pharma Ltd. and Keymed Biosciences Co. Ltd. out-licensed their co-developed CD20×CD3 bispecific antibody (ICP-B02/CM355) to startup Prolium ...